Related Experiment Videos
Pentoxifylline maintains hepatocellular function and improves cardiac performance during early sepsis
1Center for Surgical Research, Brown University School of Medicine, Providence, Rhode Island, USA.
The Journal of Trauma
|March 1, 1997
Summary
Pentoxifylline (PTX) treatment maintained hepatocellular function and improved cardiac performance in rats during early sepsis. This study investigated PTX
Area of Science:
- Sepsis Pathophysiology
- Pharmacology
- Cardiovascular Physiology
Background:
- Polymicrobial sepsis significantly depresses hepatocellular function.
- Early sepsis stages are characterized by hyperdynamic circulatory states.
- The effects of pentoxifylline (PTX) on early sepsis-induced organ dysfunction are not fully understood.
Purpose of the Study:
- To determine if PTX administration attenuates depressed hepatocellular function during early sepsis.
- To assess the impact of PTX on cardiac performance in the hyperdynamic phase of sepsis.
Main Methods:
- Sepsis was induced in rats via cecal ligation and puncture (CLP).
- PTX or saline was administered intravenously 1 hour post-CLP.
- Hepatocellular function was measured using indocyanine green clearance.
- Cardiac output and left ventricular performance were assessed using dye dilution and a heart performance analyzer.
Main Results:
- CLP led to significant depression of hepatocellular function at 2 and 5 hours.
- PTX treatment preserved hepatocellular function at levels comparable to sham controls.
- While cardiac output increased post-CLP, PTX significantly enhanced cardiac performance indicators, including +dP/dtmax and peak systemic pressure.
Conclusions:
- Pentoxifylline demonstrates potential as an adjunct therapy for sepsis.
- PTX effectively maintains hepatocellular function during early hyperdynamic sepsis.
- PTX improves cardiac performance in the early stages of polymicrobial sepsis.